Clinical Relevance of Rifampicin‐Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients
Vanessa B. Vogensen, Mathieu S. Bolhuis, Marieke G. G. Sturkenboom, Tjip S. van der Werf, Wiel C. M. de Lange, Richard M. Anthony, Dick van Soolingen, Jan-Willem Alffenaar, Huib A. M. Kerstjens, Onno W. Akkerman
Abstract
/MIC > 100. This study showed a clinically significant 39% decrease in moxifloxacin exposure when rifampicin was co-administered. Moxifloxacin dose adjustment may compensate for this drug-drug interaction. Further exploring the impact of higher doses of these drugs in patients with isoniazid resistance or intolerance is paramount.
Topics & Concepts
MoxifloxacinRifampicinMedicineIsoniazidTuberculosisInternal medicineAntibacterial agentClinical significanceEthambutolAntibioticsMycobacterium tuberculosisPharmacologyAdverse effectRifapentinePharmacotherapyDrug resistanceRetrospective cohort studyPyrazinamideDrug interactionSurgeryPharmacokineticsDrugTuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisDrug-Induced Adverse Reactions